Reto Guler

University Of Cape Town

$323,086

Attributed

$646,171

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $132.6K · FY2021–25

$200K$150K$100K$50K$0

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$646,171 · 1

By mechanism

R01$646,171 · 1

Top collaborators

Winston Alexander Hide5 shared

Most similar at University Of Cape Town

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Gene Expression”

Evan Z Macosko · Broad Institute, Inc.$35,121,158
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$26,358,801
Benjamin E Deverman · Broad Institute, Inc.$16,920,984
Tomasz Nowakowski · University Of California, San Francisco$15,628,426
Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Crystal Mackall · Children'S Hosp Of Philadelphia$14,040,300

Research focus

Gene ExpressionGenerationsAfricaAffectAntimicrobialAfricanAntisense OligonucleotidesAntisense Oligonucleotide TherapyAutomobile DrivingAntibiotic TherapyBioinformaticsBiologyCessation Of LifeChronic InfectionCodeCohortCommunicable DiseasesDesignDiagnostic BiomarkerDifferential ExpressionDrug TargetingElementsEpigenetic ProcessGenes

Grant awards (5)

Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$129,659

R01 · FY2025 · AI · contact PI

Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$131,718

R01 · FY2024 · AI · contact PI

Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$131,642

R01 · FY2023 · AI · contact PI

Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$132,596

R01 · FY2022 · AI · contact PI

Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$120,556

R01 · FY2021 · AI · contact PI